Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
acute leukaemia
diagnostic haematology
flow cytometry
minimal residual disease
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
24
09
2021
accepted:
24
11
2021
pubmed:
10
12
2021
medline:
21
4
2022
entrez:
9
12
2021
Statut:
ppublish
Résumé
The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.
Identifiants
pubmed: 34881427
doi: 10.1111/bjh.17992
pmc: PMC9299641
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
Antigens, CD19
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
76-81Informations de copyright
© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Cytometry B Clin Cytom. 2014 Sep;86(5):329-39
pubmed: 24845957
Br J Haematol. 2021 May;193(3):602-612
pubmed: 33715150
Leukemia. 2020 Nov;34(11):3064-3069
pubmed: 32103145
Cytometry B Clin Cytom. 2018 Jan;94(1):112-120
pubmed: 27598971
J Clin Oncol. 2009 Nov 1;27(31):5168-74
pubmed: 19805690
Clin Cancer Res. 2015 Sep 15;21(18):4035-9
pubmed: 26374073
Blood. 2015 Jun 25;125(26):3996-4009
pubmed: 25999452
Blood. 2017 Jan 19;129(3):347-357
pubmed: 27903527
Curr Treat Options Oncol. 2021 Jun 7;22(7):62
pubmed: 34097135
Blood. 2021 Apr 8;137(14):1879-1894
pubmed: 33150388
Blood Cancer J. 2017 Dec 20;7(12):659
pubmed: 29259173
N Engl J Med. 2017 Mar 2;376(9):836-847
pubmed: 28249141
Leukemia. 2007 Apr;21(4):706-13
pubmed: 17287857